Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Vijay Trisal, April K.S. Salama, Marshall M. Urist, Gregory A. Daniels, Daniel G. Coit, Merrick I. Ross, Nicole R. McMillian, Kenneth K. Tanabe, Dominick J. DiMaio, Joseph J. Skitzki, John A. Thompson, Brian R. Gastman, Christopher K. Bichakjian, Ryan C. Fields, Alain Algazi, Douglas B. Johnson, Martin D. Fleming, Anthony J. Olszanski, Richard W. Joseph, Rene Gonzalez, Patrick A. Ott, Valerie Guild, William E. Carson, Susan M. Swetter, Miguel A. Materin, Aparna Priyanath Gupta, Julie R. Lange, Mary C. Martini, Javier F. Torres-Roca, Anita M. Engh, Robert H.I. Andtbacka
Publikováno v:
Journal of the National Comprehensive Cancer Network. 14:945-958
The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting exten
Autor:
Anita M. Engh, Ryan C. Fields, F. Stephen Hodi, Nicole R. McMillian, Martin D. Fleming, Anthony J. Olszanski, Robert H.I. Andtbacka, John A. Thompson, Miguel A. Materin, Kenneth K. Tanabe, April K.S. Salama, Daniel G. Coit, Valerie Guild, Joseph J. Skitzki, Rene Gonzalez, Marc Ernstoff, Dominick J. DiMaio, Merrick I. Ross, Susan M. Swetter, Javier F. Torres-Roca, William E. Carson, Julie R. Lange, Christopher K. Bichakjian, Jeffrey A. Sosman, Vijay Trisal, Mary C. Martini, Richard W. Joseph, Allan C. Halpern, Gregory A. Daniels, Marshall M. Urist, Alain Algazi
Publikováno v:
Journal of the National Comprehensive Cancer Network. 14:450-473
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. De
Publikováno v:
Journal of the National Comprehensive Cancer Network. 7:308-317
Sentinel lymph node (SLN) biopsy has emerged over the past 2 decades as a rational approach for staging regional lymph nodes in patients with clinically node-negative melanoma (stage I and II disease). Large multi-institutional studies have confirmed